CENTURY THERAPEUTICS INC (IPSC) Stock Price, Forecast & Analysis
USA - NASDAQ:IPSC - US15673T1007 - Common Stock
IPSC Key Statistics, Chart & Performance
The current stock price of IPSC is 0.5831 USD. In the past month the price increased by 13.6%. In the past year, price decreased by -53.72%.
IPSC Latest News, Press Relases and Analysis
IPSC Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.07 | 385.18B | ||
| AMGN | AMGEN INC | 13.68 | 160.66B | ||
| GILD | GILEAD SCIENCES INC | 14.63 | 148.64B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.12 | 109.11B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.48 | 69.08B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 894.2 | 59.78B | ||
| ARGX | ARGENX SE - ADR | 61.04 | 50.39B | ||
| INSM | INSMED INC | N/A | 40.08B | ||
| ONC | BEONE MEDICINES LTD-ADR | 5.01 | 34.10B | ||
| NTRA | NATERA INC | N/A | 27.30B | ||
| BNTX | BIONTECH SE-ADR | N/A | 24.98B | ||
| BIIB | BIOGEN INC | 9.22 | 22.62B |
Related stock screener links
About IPSC
Company Profile
Century Therapeutics, Inc. engages in the development of off-the-shelf cell therapies to advance the course of cancer care. The company is headquartered in Philadelphia, Pennsylvania and currently employs 140 full-time employees. The company went IPO on 2021-06-17. The firm is focused on developing transformative allogeneic cell therapies to create products for the treatment of both solid tumor and hematological malignancies and autoimmune diseases. The firm has created allogeneic cell therapy platform that includes induced pluripotent stem cells (iPSCs), differentiation know-how to generate immune effector cells from iPSCs, or iPSC- derived cells, clustered regularly interspaced short palindromic repeats, to incorporate multiple transgenes and remove target genes. The Company’s product candidates include CNTY-101, CNTY-308, CNTY-341, CNTY-107, and CNTY-104. Its lead product candidate CNTY-101 is a CAR-iNK cell therapy with six precision gene edits in a Phase I clinical trial for patients with B-cell mediated autoimmune diseases. CNTY-308 is a CD19-targeted, iPSC derived CAR T cell therapy. CNTY-341 is a dual-targeted CD19 and CD22 iPSC-derived CAR-T cell therapy.
Company Info
CENTURY THERAPEUTICS INC
25 N 38Th Street, 11Th Floor
PHILADELPHIA PENNSYLVANIA US
CEO: Osvaldo Flores
Employees: 140
Phone: 12159814000
CENTURY THERAPEUTICS INC / IPSC FAQ
What does IPSC do?
Century Therapeutics, Inc. engages in the development of off-the-shelf cell therapies to advance the course of cancer care. The company is headquartered in Philadelphia, Pennsylvania and currently employs 140 full-time employees. The company went IPO on 2021-06-17. The firm is focused on developing transformative allogeneic cell therapies to create products for the treatment of both solid tumor and hematological malignancies and autoimmune diseases. The firm has created allogeneic cell therapy platform that includes induced pluripotent stem cells (iPSCs), differentiation know-how to generate immune effector cells from iPSCs, or iPSC- derived cells, clustered regularly interspaced short palindromic repeats, to incorporate multiple transgenes and remove target genes. The Company’s product candidates include CNTY-101, CNTY-308, CNTY-341, CNTY-107, and CNTY-104. Its lead product candidate CNTY-101 is a CAR-iNK cell therapy with six precision gene edits in a Phase I clinical trial for patients with B-cell mediated autoimmune diseases. CNTY-308 is a CD19-targeted, iPSC derived CAR T cell therapy. CNTY-341 is a dual-targeted CD19 and CD22 iPSC-derived CAR-T cell therapy.
What is the stock price of CENTURY THERAPEUTICS INC today?
The current stock price of IPSC is 0.5831 USD. The price decreased by -1.5% in the last trading session.
Does CENTURY THERAPEUTICS INC pay dividends?
IPSC does not pay a dividend.
How is the ChartMill rating for CENTURY THERAPEUTICS INC?
IPSC has a ChartMill Technical rating of 5 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the analyst forecast for IPSC stock?
11 analysts have analysed IPSC and the average price target is 5.1 USD. This implies a price increase of 774.64% is expected in the next year compared to the current price of 0.5831.
What is the expected growth for IPSC stock?
The Revenue of CENTURY THERAPEUTICS INC (IPSC) is expected to grow by 3161.57% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
Who owns CENTURY THERAPEUTICS INC?
You can find the ownership structure of CENTURY THERAPEUTICS INC (IPSC) on the Ownership tab.
IPSC Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to IPSC. When comparing the yearly performance of all stocks, IPSC is a bad performer in the overall market: 89.43% of all stocks are doing better.
IPSC Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to IPSC. While IPSC has a great health rating, there are worries on its profitability.
IPSC Financial Highlights
Over the last trailing twelve months IPSC reported a non-GAAP Earnings per Share(EPS) of -0.29. The EPS increased by 85.71% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -8.18% | ||
| ROE | -11.09% | ||
| Debt/Equity | 0 |
IPSC Forecast & Estimates
11 analysts have analysed IPSC and the average price target is 5.1 USD. This implies a price increase of 774.64% is expected in the next year compared to the current price of 0.5831.
For the next year, analysts expect an EPS growth of 92.96% and a revenue growth 3161.57% for IPSC